MediciNova
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- -
- Market Cap
- $71.6M
- Introduction
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on the...
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 255
- Registration Number
- NCT01982942
- Locations
- 🇺🇸
University at Buffalo, The State University of New York, Buffalo, New York, United States
🇺🇸Cornell Medical College, New York, New York, United States
🇺🇸University of Virginia Charlottesville, Charlottesville, Virginia, United States
Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 19
- Registration Number
- NCT01551316
- Locations
- 🇺🇸
Central Texas Health Research, New Braunfels, Texas, United States
🇺🇸Sylvana Research Associates, San Antonio, Texas, United States
Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 48
- Registration Number
- NCT01013142
- Locations
- 🇺🇸
California Research Medical Group, INC, Fullerton, California, United States
🇺🇸Dedicated Phase I, Phoenix, Arizona, United States
🇺🇸Vita Research Solutions & Medical Center, Inc., Tamarac, Florida, United States
Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 176
- Registration Number
- NCT00838591
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma
- Conditions
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2011-10-07
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 29
- Registration Number
- NCT00683449
- Locations
- 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸Maricopa Medical Center; Dept. of Emergency Medicine, Phoenix, Arizona, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 17
- Registration Number
- NCT00679263
- Locations
- 🇺🇸
PRA International, Lenexa, Kansas, United States
🇺🇸Northeast Medical Research Associates, North Dartmouth, Massachusetts, United States
🇺🇸Clinical Research of the Ozarks, Rolla, Missouri, United States
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 296
- Registration Number
- NCT00295854
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Adult and Pediatric Urology, Plantation, Florida, United States
🇺🇸Georgis Patsias, MD., PA, Wellington, Florida, United States